Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5FU

被引：1
|
作者：
Beretta, GD
Cascinu, S
Zaniboni, A
Ratti, R
Giordani, P
Catalano, V
Martignoni, G
Barni, S
Frontini, L
Labianca, R
机构：
[1] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[2] Univ Messina, Messina, Italy
[3] Casa Cura Poliambulanza, Brescia, Italy
[4] Casa Cura Igea, Milan, Italy
[5] Osped Muraglia, Pesaro, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)80689-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
256
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [1] Oxaliplatin (L-OHP) in combination with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (CRC) patients (PTS).
    Di Stefano, A
    Calandri, C
    Benedetti, G
    Poggi, B
    Mazzoni, F
    Marrocolo, F
    Spagnuolo, P
    Rimondini, S
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [2] Bi-fractionated oxaliplatin (L-OHP) plus 5-fluorouracil (5FU)/leucovorin (LV) for elderly patients (pts) with advanced colorectal cancer (CRC).
    Massacesi, C
    Lippe, P
    Recchia, F
    Marcucci, F
    Rocchi, M
    Cesta, A
    Pilone, A
    Cappelletti, C
    Bonsignori, M
    Mattioli, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
  • [3] Symptomatic effects of methotrexate, 5fluorouracil and leucovorin in advanced colorectal cancer after failure of 5FU continuous infusion
    Cascinu, S
    Battelli, N
    Scartozzi, M
    Baldelli, AM
    Cellerino, R
    GI CANCER, 1998, 2 (03): : 203 - 206
  • [4] Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer.
    Abón, G
    Muñoz, A
    Rubio, I
    Mañé, JM
    Ferreiro, J
    Fernández, R
    Fuente, N
    López-Argumedo, G
    Barceló, R
    Vivanco, GL
    ANNALS OF ONCOLOGY, 2000, 11 : 48 - 49
  • [5] Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients
    Smid, Kees
    Meijer, Erik
    Pham, Thang V.
    de Reus, Inge
    Piersma, Sander R.
    Peters, Godefridus J.
    Jimenez, Connie R.
    CANCER RESEARCH, 2015, 75
  • [6] Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer
    Bosset, JF
    DeGrammont, A
    Milan, C
    Rougier, P
    Bouche, O
    Etienne, PL
    Morvan, F
    Louvet, C
    Guillot, T
    Bedenne, L
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 702 - 702
  • [7] Final results of first line treatment with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A multicenter phase II study.
    Souglakos, J
    Kouroussis, C
    Ziras, N
    Malamos, N
    Potamianou, A
    Mavroudis, D
    Kakolyris, S
    Androulakis, N
    Vardakis, N
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [8] Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients
    Mini, E
    Pinto, C
    Angelelli, B
    Dentico, P
    Piana, E
    Nobili, S
    Gentile, AL
    Scicolone, S
    Mazzei, T
    Martoni, A
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [9] Second and third-line chemotherapy (CT) with oxaliplatin L-OHP), 5-fluorouracil (FU) and leucovorin (LV) in patients (pts) with advanced colorectal cancer (ACC): a new schedule.
    D'Andrea, M
    Bari, M
    Sartori, D
    Silvestri, B
    Azzarello, G
    Rosetti, F
    Zardo, S
    Porcellini, A
    Vinante, O
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [10] CPT-11 and L-OHP combination versus alternated combination of LV5FU2+CPT-11/LV5FU2+L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results
    Becouam, Y
    Mousseau, M
    Gamelin, E
    Coudert, B
    Marceau-Suissa, J
    Bekradda, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S71 - S71
12345